

**Additional File 1**

Results of a multivariate survival analysis on the influence of clinicopathological variables including PgR in the intermediate Ki67 labeling index group

Characteristics	RFS			CSS		
	HR	<i>P</i>	95%CI	HR	<i>P</i>	95%CI
PgR expression	Referent					
≥ 20%	Referent					
< 20%	4.72	0.00042	1.99-11.19	11.09	0.00025	3.06-40.18
Menopausal status	Referent					
Pre-	Referent					
Post-	1.18	0.71	0.50-2.79	0.41	0.15	0.12-1.39
Pathological T stage	Referent					
T 1-2	Referent					
T 3-4	1.19	0.75	0.41-3.45	0.31	0.18	0.05-1.75
Pathological N stage	Referent					
N 0	Referent					
N 1-3	3.17	0.020	1.20-8.39	2.64	0.10	0.83-8.41
Histological grade	Referent					
1,2	Referent					
3	1.25	0.59	0.56-2.82	2.44	0.11	0.81-7.36
Adjuvant chemotherapy	Referent					
No	Referent					
Yes	0.81	0.63	0.35-1.90	0.65	0.40	0.24-1.77
Adjuvant endocrine therapy	Referent					
No	Referent					
Yes	0.56	0.39	0.15-2.11	1.41	0.75	0.17-11.91

## Abbreviations:

RFS, Recurrence-free survival; CSS, Cancer-specific survival; HR, Hazard Ratio; 95% CI, 95% Confidence interval; PgR, progesterone receptor.